Puma Biotechnology | PBYI - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Agios Pharmaceuticals USD 1.19B 91.22M 2025-12
Alnylam Pharmaceuticals USD 789.18M 555.28M 2025-12
Amgen USD 8.66B 961M 2025-12
Biogen USD 18.21B 573.5M 2025-09
BioMarin Pharmaceutical USD 6.09B 30.29M 2025-12
Daiichi Sankyo JPY 1.71T 57.86B 2025-12
Esperion Therapeutics USD -301.96M 149.4M 2025-12
Exelixis USD 2.16B 619K 2025-12
Gilead Sciences USD 22.62B 1.16B 2025-12
Glaxosmithkline GBP 22.06B 360M 2025-12
Incyte USD 5.17B 516.28M 2025-12
MacroGenics USD 55.59M 11.41M 2025-12
Moderna USD 8.65B 680M 2025-12
Novartis USD 46.13B 1.38B 2025-12
Pfizer USD 92.8B 4.11B 2025-09
PTC Therapeutics USD -205.31M 49.56M 2025-12
Puma Biotechnology USD 115.27M 10.55M 2025-09
Regeneron Pharmaceuticals USD 31.26B 299.1M 2025-12
Roche Holding CHF 33.8B 758M 2025-12
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sarepta Therapeutics USD 1.14B 179.5M 2025-12
Takeda JPY 7.64T 513.39B 2025-12
TG Therapeutics USD 648.02M 40.8M 2025-12
Ultragenyx Pharmaceutical USD 9.16M 142.13M 2025-09
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12
Vertex Pharmaceuticals USD 18.67B 1.35B 2025-12